Phase 3 Clinical Trials With Primary Completion Dates in November 2020
This is a list of Phase 3 trials with primary completion dates in November 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ADMS | Adamas Pharmaceuticals, Inc. | 2020-11-01 | Phase 3 | NCT03567057 | A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment |
| APRE | Aprea Therapeutics, Inc. | 2020-11-01 | Phase 3 | NCT03745716 | APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) |
| ATRA | Atara Biotherapeutics, Inc. | 2020-11-01 | Phase 3 | NCT03394365 | Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy |
| ATRA | Atara Biotherapeutics, Inc. | 2020-11-01 | Phase 3 | NCT03392142 | Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab |
| CPHI | China Pharma Holdings, Inc. | 2020-11-01 | Phase 3 | NCT03660059 | A Study to Assess Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX) |
| EBS | Emergent BioSolutions Inc. | 2020-11-01 | Phase 3 | NCT03877926 | VELOCITY: An Anthrax Vaccine Clinical Study |
| FULC | Fulcrum Therapeutics, Inc. | 2020-11-01 | Phase 3 | NCT04511819 | Losmapimod Safety and Efficacy in COVID-19 |
| HLUYY | H. Lundbeck A/S | 2020-11-01 | Phase 3 | NCT03548584 | A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type |
| IRWD | Ironwood Pharmaceuticals, Inc. | 2020-11-01 | Phase 3 | NCT03561883 | Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors |
| NEPH | Nephros, Inc. | 2020-11-01 | Phase 3 | NCT03644264 | PA21 Safety and Efficacy in Adult Chinese Subjects |
| OVID | Ovid Therapeutics Inc. | 2020-11-01 | Phase 3 | NCT04106557 | A Study of OV101 in Individuals With Angelman Syndrome (AS) |
| SPPI | Spectrum Pharmaceuticals, Inc. | 2020-11-01 | Phase 3 | NCT02563561 | A Study of Intravesical Apaziquone as a Surgical Adjuvant in Patient Undergoing TURBT |
| TEVA | Teva Pharmaceutical Industries Limited | 2020-11-01 | Phase 3 | NCT03879837 | Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg |
| TGTX | TG Therapeutics, Inc. | 2020-11-01 | Phase 3 | NCT02612311 | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia |
| UROV | Urovant Sciences Ltd. | 2020-11-01 | Phase 3 | NCT03902080 | Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) |
| VNDA | Vanda Pharmaceuticals Inc. | 2020-11-01 | Phase 3 | NCT04140695 | Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2) |